Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Surg Endosc ; 31(6): 2411-2425, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-27633439

RESUMEN

BACKGROUND: Acute gastrointestinal (GI) wall defects contain a high risk of morbidity and mortality and may be closed endoscopically by a full-thickness over-the-scope clip (OTSC). METHODS: Unselected consecutive patients presenting with acute non-surgical perforations or postoperative anastomotic leaks or perforations underwent attempted OTSC placement as primary closure method after interdisciplinary consensus in three tertiary referral centres. Their clinical data and intervention characteristics were evaluated in an intention to treat analysis during a 24-month period to assess closure rates, 30-day mortality, hospitalization and comorbidity. RESULTS: In total, 34 patients (16 females, 18 males, 69.5 years) were included with 22 non-surgical perforations and 12 postoperative anastomotic leaks or perforations. Definitive closure of the perforations and leaks was achieved in 26/34 patients (76.5 %). Successful closure of the GI wall defect resulted in a significantly shorter hospital stay (8 days, p = 0.03) and was significantly correlated with comorbidity (r = 0.56, p = 0.005). In the group with OTSC failure, hospitalization was 18 days and 6 of 8 patients (75 %) required immediate surgery. Three deaths occurred in the group with successful OTSC closure due to comorbidity, while one death in the OTSC failure group was related to a refractory perforation. Favourable indications and locations for a successful OTSC procedure were identified as PEG complications, endoscopic or postoperative leaks of stomach, colon or rectum, respectively. CONCLUSIONS: In unselected patients, OTSC was effective for closure of acute GI wall defects in more than 75 % of all patients. Clinical success and short hospitalization were best achieved in patients without comorbidity, but closure of the perforation or the anastomotic leak was found to be not the only parameter relevant for patient outcome and mortality.


Asunto(s)
Fuga Anastomótica/cirugía , Endoscopía Gastrointestinal/instrumentación , Perforación Intestinal/cirugía , Técnicas de Cierre de Heridas/instrumentación , Enfermedad Aguda , Adulto , Anciano , Anciano de 80 o más Años , Fuga Anastomótica/epidemiología , Comorbilidad , Endoscopía Gastrointestinal/métodos , Femenino , Estudios de Seguimiento , Hospitalización/estadística & datos numéricos , Humanos , Análisis de Intención de Tratar , Perforación Intestinal/epidemiología , Perforación Intestinal/etiología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Centros de Atención Terciaria , Resultado del Tratamiento
2.
Z Gastroenterol ; 52(9): 1066-74, 2014 Sep.
Artículo en Alemán | MEDLINE | ID: mdl-25198086

RESUMEN

INTRODUCTION: Capsule endoscopy (CE) is firmly established as a standard procedure in the diagnostic algorithm of mid gastrointestinal (GI) bleeding. Despite its excellent diagnostic yield, missing expertise, reading time and financial expenditure limit an area-wide availability. A multicentric cooperation might compensate these disadvantages. METHODS: The CE device was bought by a centrally located hospital (CH). CE-equipment is transported to the network partner (NP) on request and the procedure performed at the spot. Video reading is exclusively done in the CH. RESULTS: Between January 2002 and July 2013, 1026 CE (548 m, 478f; 64 ±â€Š16, 13 - 93 yrs.) were performed within the network. 744/1026 (73 %) CE were done at 17 NP, 282/1026 (27 %) in the CH. Between 2002 (n = 39) and 2012 (n = 136) the annual number of CE increased threefold. Leading indication for CE was suspected mid GI-bleeding (80 %). Mean latencies between requested date and actual examination were less than 24 h and 2 days between CE performance and report. 95 % of the capital investment in each cooperating hospital could be avoided by sharing one workstation within the network. CONCLUSION: The experience from more than 1000 CE show that long-term multicentric utilization of CE equipment is feasible. Such a network runs at stable procedural quality levels similar to an in-house supply, allows an economic as well as area-wide availability of CE and improves reading expertise by centralized video evaluation.


Asunto(s)
Endoscopía Capsular/estadística & datos numéricos , Hemorragia Gastrointestinal/epidemiología , Hemorragia Gastrointestinal/patología , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Sector Privado/estadística & datos numéricos , Programas Médicos Regionales/estadística & datos numéricos , Revisión de Utilización de Recursos , Alemania/epidemiología , Humanos , Prevalencia
3.
Int Arch Allergy Immunol ; 160(4): 350-5, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23183101

RESUMEN

BACKGROUND AND AIMS: Mast cells, which are important effector cells in food allergy, require a special histologic treatment for quantification in endoscopic gastrointestinal samples. The objective of this study was to investigate whether mast cell tryptase (T), a typical mast cell-associated marker, may help to detect patients with food allergy. METHODS: Mast cell T was investigated from 289 colorectal samples of 73 controls, 302 samples from 43 patients with food allergy and gastrointestinal symptoms, and 72 samples from 12 patients with partial or complete remission of allergic symptoms. Endoscopically taken samples were immediately put into liquid nitrogen, mechanically homogenized by a micro-dismembrator with three homogenization steps and tissue T content (ng T/mg wet weight) was measured by fluoroenzyme immunoassay. RESULTS: Tissue T levels from the lower gastrointestinal tract were significantly elevated (p < 0.0001) in patients with manifest gastrointestinal allergy (median: 55.7, range: 9.3-525.0) compared with controls (median: 33.5, range: 8.0-154.6). A subgroup of 12 patients with remission of allergy showed markedly decreased symptom scores and mucosal T levels after more than 1 year of antiallergic therapy (pretreatment median: 54.1, range: 37.0-525.0 and posttreatment median: 28.4, range: 19.8-69.1; p = 0.01). CONCLUSIONS: High T levels in the gut of food-allergic patients support the role of stimulated mast cells or an increased mast cell number.


Asunto(s)
Hipersensibilidad a los Alimentos/diagnóstico , Tracto Gastrointestinal/enzimología , Mucosa Intestinal/enzimología , Mastocitos/enzimología , Triptasas/metabolismo , Adulto , Biomarcadores/análisis , Femenino , Hipersensibilidad a los Alimentos/enzimología , Hipersensibilidad a los Alimentos/patología , Hipersensibilidad a los Alimentos/terapia , Tracto Gastrointestinal/patología , Humanos , Mucosa Intestinal/inmunología , Mucosa Intestinal/patología , Masculino , Mastocitos/inmunología , Mastocitos/metabolismo
4.
Allergy ; 67(2): 286-92, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22035500

RESUMEN

BACKGROUND: Food allergy may present with a plethora of gastrointestinal and extraintestinal symptoms such as abdominal pain, diarrhea, cardiocirculatory symptoms, cutaneous reactions, or rhinitis. Macropathological lesions like lymphofollicular hyperplasia and erosive or ulcerative lesions have seldom been described in gastroscopy and colonoscopy previously. METHODS: Fifteen patients presenting with unspecific abdominal symptoms in which food allergy was detected in due course were included. During the examination process, those patients showed various indications for small-bowel capsule endoscopy, such as weight loss and anemia. RESULTS: Fourteen (93.3%) of the 15 small-bowel capsule endoscopies could be assessed, showing nonerosive lesions such as erythema, swelling, and lymphoid hyperplasia in 8 patients (57.1%) and erosive lesions such as aphthoid lesions, erosions, and petechiae in 4 patients (28.6%) with food allergy. CONCLUSION: In 15 patients with confirmed food allergy and after exclusion of other diseases, 12 (85.7%) showed various unspecific nonerosive or erosive mucosal lesions within the small bowel, resulting, however, partially in grave consequences such as anemia. Lymphoid hyperplasia was the most prominent finding in 7 patients (50%), albeit infectious disease had been excluded. Anemia improved within 1 year after adequate antiallergic treatment.


Asunto(s)
Endoscopía Capsular/métodos , Hipersensibilidad a los Alimentos/diagnóstico , Enfermedades Gastrointestinales/diagnóstico , Intestino Delgado/patología , Adolescente , Adulto , Alérgenos/efectos adversos , Alérgenos/inmunología , Femenino , Hipersensibilidad a los Alimentos/patología , Enfermedades Gastrointestinales/patología , Humanos , Mucosa Intestinal/patología , Masculino , Persona de Mediana Edad , Adulto Joven
5.
Colorectal Dis ; 14(9): 1121-5, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22122526

RESUMEN

AIM: Perforation occurs rarely after colonoscopy, but is associated with high morbidity and mortality. In this study, we assessed the perforation rate in our hospital, its clinical diagnosis and the long-term outcome. METHOD: During the study period, 7535 examinations were performed, of which 4830 were diagnostic and 2705 therapeutic. The latter included polypectomy, endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), dilatation and argon plasma coagulation (APC). RESULTS: Overall, 25 (0.33%) perforations occurred with two (0.026%) procedure-related deaths. Seven (0.14%) perforations occurred during a diagnostic procedure and 18 (0.67%) occurred during a therapeutic procedure. Dilation, submusous resection (SMR) and APC accounted for more perforations than polypectomy or diagnostic colonoscopy. Pre-existing gastrointestinal disease was present in 24 (96%) perforations. Three (12%) patients were treated conservatively and 22 (88%) underwent surgery. The site of perforation was closed by suture in four (18%) patients and resected with colonic anastomosis in five (23%) patients. Two patients underwent endoscopic clipping. A stoma was created after resection in 13 (59%) patients. CONCLUSION: Death from perforation after colonoscopy is rare, occurring in 1/3500 examinations. The risk is increased in therapeutic colonoscopy and in the presence of previous gastrointestinal disease. Dilatation, SMR and APC appeared to confer a higher risk of perforation than polypectomy or diagnostic colonoscopy.


Asunto(s)
Colonoscopía/efectos adversos , Perforación Intestinal , Adulto , Anciano , Anciano de 80 o más Años , Coagulación con Plasma de Argón/efectos adversos , Disección/efectos adversos , Femenino , Alemania , Hospitales Universitarios/estadística & datos numéricos , Humanos , Enfermedades Intestinales/complicaciones , Perforación Intestinal/diagnóstico , Perforación Intestinal/etiología , Perforación Intestinal/cirugía , Masculino , Persona de Mediana Edad , Factores de Riesgo
6.
Z Gastroenterol ; 50(12): 1302-9, 2012 Dec.
Artículo en Alemán | MEDLINE | ID: mdl-23225559

RESUMEN

BACKGROUND: Non-immunological types of foodstuffs intolerance are reported by about 15-20% people of the population. The intolerance of histamine and to some extent of other biogenic amines (such as cadaverine, putrescine, tyramine etc.) plays an important role in the differential diagnosis of the foodstuff intolerances and has to be strictly separated from immunologically mediated foodstuffs reactions (foodstuffs allergies, 2-5% of the population). METHODS: Clinical data from the Erlangen interdisciplinary data register of allergic and chronic inflammatory gastro-intestinal diseases were analysed respecting the existence of a histamine intolerance, then classified and summarised; in addition a selective literature research was undertaken in May 2011. RESULTS: In non-immunological cases of foodstuffs intolerance, the patient's intolerance of histamine plays quite a significant role, clinically it has been exactly proven only in a small subgroup of patients by standardised blinded provocation reactions. The histamine intolerance syndrome (HIS) often presents in a non-specific manner and has to be separated from other pseudo-allergic reactions, idiopathic intolerance reactions, organic differential diagnosis (for example, chronic infections, allergies, mastocytosis etc.) as well as medicamentous adverse effects and psychosomatic reactions. CONCLUSION: The clinical picture of histamine intolerance should be definitely assured, after the exclusion of other differential diagnosis, by standardised histamine provocation. The avoidance of histamine and biogenic amines, the use of antihistaminics and the instauration of a proportionate nutrient matter are the most important therapeutic options next to a detailed education of the patient.


Asunto(s)
Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/epidemiología , Hipersensibilidad a los Alimentos/diagnóstico , Hipersensibilidad a los Alimentos/epidemiología , Histamina/efectos adversos , Sistema de Registros , Comorbilidad , Diagnóstico Diferencial , Hipersensibilidad a las Drogas/inmunología , Hipersensibilidad a los Alimentos/inmunología , Alemania/epidemiología , Histamina/inmunología , Humanos , Incidencia , Factores de Riesgo
7.
J Physiol Pharmacol ; 71(5)2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33475093

RESUMEN

Gastrointestinal bleeding (GIB) still presents a demanding situation with high morbidity and mortality rates; thus hemostatic powders such as EndoClot (EC) have been developed to improve endoscopic armament. The aim of the present study was to determine which indications triggered the application of EC and to assess resulting hemostasis rates. Forty three patients undergoing endoscopical procedures in three hospitals; two tertiary care and one university hospital, were included. EC was applied in 48 endoscopies in 43 patients (27 male, age 65.5 years, range 28 - 92 years) following four different indications. EC was used in active GIB as rescue or first-line therapy giving a short-term and long-term hemostasis in 13/17 patients (76.5%). In the setting of non-active GIB, following conventionally achieved hemostasis or endoscopic interventions, EC was found to prevent bleeding in 19/21 patients (90.4%). EC induced hemostasis in 8/10 patients (80%) with impaired coagulation. EC failures resulted from tumor bleeding, Forrest I lesions or perforated duodenal ulcers. No major adverse events were recorded and one technical failure (2.1%) occurred. EC was applied as first line or salvage treatment in ongoing bleedings with promising results. Furthermore, EC was used after successful hemostasis or following endoscopic interventions to further reduce re-bleeding rates. We saw promising results in all indications, albeit lacking a control group.


Asunto(s)
Endoscopía Gastrointestinal , Hemorragia Gastrointestinal/prevención & control , Hemostáticos/farmacología , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Hemostáticos/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Polvos , Estudios Retrospectivos , Tracto Gastrointestinal Superior
8.
J Physiol Pharmacol ; 70(6)2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32203937

RESUMEN

Vitamin K antagonists (VKA) continue to be the standard of long-term anticoagulation. Direct oral anticoagulants(DOAC) are increasingly used. In many trials DOAC were at least as effective as VKA. In this study we evaluate the bleeding profiles, frequencies and etiologies of patients receiving DOAC versus VKA in a real-life setting. All patients presenting with suspected gastrointestinal bleeding (GIB) in the emergency department of the University Hospital Erlangen in one year were enrolled in this study. They were looked up for the intake of either DOAC (dabigatran, rivaroxaban and apixaban) or VKA. The results showed that 406 patients with suspected GIB were admitted to the emergency unit of the University Hospital Erlangen. In 228 of those patients GIB could be verified (56.2%). Fifty four of those patients (23.7%) were administered either VKA or DOAC. In 35 of those 54 patients (64.8%) GIB was classified as 'major bleeding'. In 27 patients with administration of VKA upper GIB was recorded and lower GIB was detected four times. In 16 patients with administration of DOAC upper GIB was found and lower GIB was found in 7 patients. The presented data do not show higher GIB rates for DOAC (mainly dabigatran and rivaroxaban), but do also not indicate a significantly higher safety of DOAC concerning GIB than VKA. This finding represents a clear contrast to the reduced bleeding rates of DOAC for intracerebral bleeding and other non-GIB events. According to our study, the absolute number of DOAC-associated GIB events is lower than in the VKA group.


Asunto(s)
Anticoagulantes/efectos adversos , Hemorragia Gastrointestinal/inducido químicamente , Vitamina K/antagonistas & inhibidores , Administración Oral , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticoagulantes/administración & dosificación , Dabigatrán/administración & dosificación , Dabigatrán/efectos adversos , Femenino , Hemorragia Gastrointestinal/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Pirazoles/administración & dosificación , Pirazoles/efectos adversos , Piridonas/administración & dosificación , Piridonas/efectos adversos , Estudios Retrospectivos , Rivaroxabán/administración & dosificación , Rivaroxabán/efectos adversos , Adulto Joven
9.
J Physiol Pharmacol ; 66(4): 549-56, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26348079

RESUMEN

Mast cells secrete numerous mediators and this study investigated plasma levels of histamine, and tumor necrosis factor alpha (TNF-α) in chronic inflammatory bowel disease (IBD). Plasma levels of histamine were determined in 68 patients with Crohn's disease (CD), 22 with ulcerative colitis (UC) and 13 controls. TNF-α levels were assessed in 29 CD patients, 11 UC patients, and in 11 controls. Plasma histamine levels in the control group were 0.25 ng (0.14 - 0.33) and showed no difference to CD (0.19 ng, 0.09 - 0.35) or UC (0.23 ng, 0.11 - 0.60). Significantly lower histamine levels were only found in CD patients on 5-aminosalicylic acid treatment (P ≤ 0.04). Plasma TNF-α levels in the control group were significantly lower 0.44 ml/m(2) (0 - 1.15) than in CD patients (4.62 ml/m(2), 1.82 - 9.22, P = 0.005) or UC (3.14 ml/m(2); 0.08 - 11.34, P = 0.01). In CD disease activity, fistula, and extraintestinal manifestations (EM) were associated with significantly higher plasma TNF-α values, but not the type of treatment. We concluded that in contrast to TNF-α, histamine levels were normal in CD and UC. There is no correlation with histamine and thus the proportion of TNF-α secreted from mast cells in the plasma in patients with IBD is less important.


Asunto(s)
Colitis Ulcerosa/sangre , Enfermedad de Crohn/sangre , Histamina/sangre , Factor de Necrosis Tumoral alfa/sangre , Adulto , Anciano , Progresión de la Enfermedad , Femenino , Humanos , Fístula Intestinal/sangre , Masculino , Persona de Mediana Edad , Adulto Joven
10.
J Physiol Pharmacol ; 63(4): 317-25, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23070080

RESUMEN

Nitric oxide (NO) is a local mediator in inflammation and allergy. The aim of this study was to investigate whether live incubated colorectal mucosal tissue shows a direct NO response ex vivo to nonspecific and specific immunological stimuli and whether there are disease-specific differences between allergic and chronic inflammatory bowel disease (IBD). We took biopsies (n=188) from 17 patients with confirmed gastrointestinally mediated food allergy, six patients with inflammatory bowel disease, and six control patients. To detect NO we employed an NO probe (WPI GmbH, Berlin, Germany) that upon stimulation with nonspecific toxins (ethanol, acetic acid, lipopolysaccharides), histamine (10(-8)-10(-4)M), and immune-specific stimuli (anti-IgE, anti-IgG, known food allergens) directly determined NO production during mucosal oxygenation. Non-immune stimulation of the colorectal mucosa with calcium ionophore (A23187), acetic acid, and ethanol induced a significant NO release in all groups and all biopsies. Whereas, immune-specific stimulation with allergens or anti-human IgE or -IgG antibodies did not produce significant release of NO in controls or IBD. Incubation with anti-human IgE antibodies or allergens produced a ninefold increase in histamine release in gastrointestinally mediated allergy (p<0.001), but anti-human IgE antibodies induced NO release in only 18% of the allergy patients. Histamine release in response to allergens or anti-human IgE antibodies did not correlate with NO release (r(2)=0.11, p=0.28). These data show that nonspecific calcium-dependent and toxic mechanisms induce NO release in response to a nonspecific inflammatory signal. In contrast, mechanisms underlying immune-specific stimuli do not induce NO production immediately.


Asunto(s)
Colon/inmunología , Hipersensibilidad a los Alimentos/inmunología , Enfermedades Inflamatorias del Intestino/inmunología , Mucosa Intestinal/inmunología , Óxido Nítrico/inmunología , Alérgenos/inmunología , Estudios de Casos y Controles , Liberación de Histamina , Humanos , Inmunoglobulina E/inmunología , Mastocitos/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA